Genexine, Inc.
KOSDAQTotal Valuation
Genexine, Inc. carries a market capitalization of 112.56B, placing it among publicly traded companies globally. Its enterprise value stands at 290.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 112.56B |
| Enterprise Value | 290.82B |
Share Statistics
Genexine, Inc. currently has 45.48M shares outstanding.
| Shares Outstanding | 45.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 45.13, and the price-to-book ratio stands at -1.60.
| PE Ratio | N/A |
| PS Ratio | 45.13 |
| PB Ratio | -1.60 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | -21.31 |
| P/OCF Ratio | -8.10 |
Enterprise Valuation
| EV / Sales | 62.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 39.34 |
Financial Position
Genexine, Inc. maintains a current ratio of 0.30, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 45.42, indicating elevated leverage, while an interest coverage ratio of -9.69 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.30 |
| Quick Ratio | 0.20 |
| Debt / Equity | 45.42 |
| Debt / EBITDA | -2.85 |
| Interest Coverage | -9.69 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -5.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1,288.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Genexine, Inc.'s stock has declined approximately -50.10081% over the past 52 weeks. The 50-day moving average sits at 3,940.50, while the 200-day moving average is 4,700.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.10081% |
| 50-Day Moving Average | 3,940.50 |
| 200-Day Moving Average | 4,700.85 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Genexine, Inc. generated 4.67B in revenue and converted that into -20.74B in net income, yielding earnings per share of -455.58. EBITDA reached -36.66B, while operating income came in at -36.66B.
| Revenue | 4.67B |
| Gross Profit | -969.84M |
| Operating Income | -36.66B |
| Pretax Income | -20.74B |
| Net Income | -20.74B |
| EBITDA | -36.66B |
| EBIT | -36.66B |
| Earnings Per Share (EPS) | -455.58 |
Balance Sheet
Genexine, Inc. holds 24.21B in cash and equivalents against 104.30B in total debt, resulting in a net debt position of 100.38B. Total book value stands at -131.55B, with working capital of -83.44B providing operational flexibility.
| Cash & Cash Equivalents | 24.21B |
| Total Debt | 104.30B |
| Net Debt | 100.38B |
| Equity (Book Value) | -131.55B |
| Book Value Per Share | -2,890.32 |
| Working Capital | -83.44B |
Cash Flow
Genexine, Inc. produced -26.01B in operating cash flow over the past twelve months. After subtracting -16.12B in capital expenditures, free cash flow totaled -42.13B - equivalent to -925.54 per share.
| Operating Cash Flow | -26.01B |
| Capital Expenditures | -16.12B |
| Free Cash Flow | -42.13B |
| FCF Per Share | -925.54 |
Margins
Genexine, Inc. operates with a gross margin of -20.77, reflecting its pricing power and cost economics. The operating margin of -785.15 and net profit margin of -444.09 provide insight into operational efficiency.
| Gross Margin | -20.77 |
| Operating Margin | -785.15 |
| Pretax Margin | -444.09 |
| Profit Margin | -444.09 |
| EBITDA Margin | -785.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.79 |
| FCF Yield | -4.69 |
Stock Splits
Genexine, Inc.'s most recent stock split took place on January 11, 2023 with a 10:13 split ratio.
| Last Split Date | 1/11/2023 |
| Split Ratio | 10:13 |
Scores
Genexine, Inc. posts an Altman Z-Score of -0.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.30 |